AN2 Therapeutics, Inc. (ANTX)
NASDAQ: ANTX · Real-Time Price · USD
4.685
-0.055 (-1.16%)
At close: Apr 29, 2026, 4:00 PM EDT
4.680
-0.005 (-0.11%)
After-hours: Apr 29, 2026, 4:04 PM EDT
AN2 Therapeutics Employees
AN2 Therapeutics had 21 employees as of December 31, 2025. The number of employees decreased by 1 or -4.55% compared to the previous year.
Employees
21
Change (1Y)
-1
Growth (1Y)
-4.55%
Revenue / Employee
n/a
Profits / Employee
-$1,674,952
Market Cap
168.64M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 21 | -1 | -4.55% |
| Dec 31, 2024 | 22 | -19 | -46.34% |
| Dec 31, 2023 | 41 | 5 | 13.89% |
| Dec 31, 2022 | 36 | 14 | 63.64% |
| Dec 31, 2021 | 22 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Protalix BioTherapeutics | 226 |
| Humacyte | 184 |
| Tonix Pharmaceuticals Holding | 142 |
| Cartesian Therapeutics | 75 |
| Precision BioSciences | 68 |
| Acumen Pharmaceuticals | 61 |
| Korro Bio | 58 |
| Corbus Pharmaceuticals Holdings | 36 |
ANTX News
- 4 weeks ago - AN2 Therapeutics Announces Initiation of Phase 2 Investigator-Initiated Clinical Trial of Epetraborole for Mycobacterium abscessus Complex Lung Disease - Business Wire
- 6 weeks ago - AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights - Business Wire
- 7 weeks ago - AN2 Therapeutics Stock Cools Off After 90% Rally - Benzinga
- 7 weeks ago - AN2 Therapeutics Transcript: Leerink Global Healthcare Conference 2026 - Transcripts
- 7 weeks ago - AN2 Therapeutics Stock Jumps 90% Monday: What's Driving The Action? - Benzinga
- 7 weeks ago - AN2 Therapeutics Announces $40 Million Private Placement Financing - Business Wire
- 2 months ago - AN2 Therapeutics Transcript: Status update - Transcripts
- 2 months ago - AN2 Therapeutics Announces Plans to Advance Oral Epetraborole into Phase 2 Study for Polycythemia Vera (PV) - Business Wire